Inspra (Eplerenone)

Eplerenone selectively antagonizes the mineralocorticoid (aldosterone) receptor in the distal nephron. By inhibiting aldosterone‑mediated sodium reabsorption, it promotes natriuresis and diuresis, reduces potassium excretion, and ultimately decreases extracellular fluid volume, leading to lower blood pressure and reduced cardiac strain.

The appropriate dose of Inspra is determined by the prescribing clinician based on the individual’s medical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose without medical guidance.

The safety of eplerenone in pregnancy or while nursing has not been definitively established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inspra (eplerenone) is a selective aldosterone antagonist with a lower affinity for androgen and progesterone receptors compared with spironolactone, potentially resulting in fewer hormonal side effects such as gynecomastia. Both agents lower blood pressure and improve heart‑failure outcomes, but choice depends on individual patient factors and tolerability.

Inspra tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging. Protect them from excess moisture, direct sunlight, and humidity to maintain product stability throughout its shelf life.

Inspra is taken orally, usually once daily, with or without food as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include hyperkalemia, which can lead to cardiac arrhythmias, and acute renal impairment. Patients should have regular monitoring of serum potassium and kidney function, especially when combined with other medications that affect electrolytes.

Inspra should be avoided in individuals with known hypersensitivity to eplerenone, those with severe hyperkalemia, or patients with significant renal impairment (eGFR <30 mL/min/1.73 m²) unless closely monitored. It is also contraindicated in patients taking potassium supplements without medical supervision.